Astria Therapeutics, Inc. (NASDAQ:ATXS) Sees Significant Decrease in Short Interest

Astria Therapeutics, Inc. (NASDAQ:ATXS) saw a large decline in short interest in the month of November. As of November 15th, there was short interest totalling 2,900,000 shares, a decline of 18.1% from the October 31st total of 3,540,000 shares. Currently, 6.0% of the company’s shares are sold short. Based on an average daily trading volume, of 321,000 shares, the short-interest ratio is currently 9.0 days.

Analyst Ratings Changes

Several analysts recently commented on ATXS shares. Wedbush reaffirmed an “outperform” rating and set a $22.00 price objective on shares of Astria Therapeutics in a research note on Tuesday, August 13th. Oppenheimer boosted their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a research report on Thursday, November 14th. Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Finally, HC Wainwright reiterated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday, November 14th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus target price of $25.60.

Astria Therapeutics Stock Down 1.0 %

Shares of NASDAQ:ATXS traded down $0.11 during mid-day trading on Friday, reaching $10.39. 139,469 shares of the stock were exchanged, compared to its average volume of 601,783. The stock’s 50 day simple moving average is $11.10 and its 200-day simple moving average is $10.62. Astria Therapeutics has a one year low of $4.50 and a one year high of $16.90. The company has a market cap of $586.35 million, a P/E ratio of -4.97 and a beta of 0.71.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the business. Quest Partners LLC increased its stake in Astria Therapeutics by 3,310.6% in the 2nd quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock valued at $29,000 after buying an additional 3,112 shares during the last quarter. PDT Partners LLC bought a new position in shares of Astria Therapeutics in the 3rd quarter valued at about $140,000. SG Americas Securities LLC acquired a new stake in shares of Astria Therapeutics in the third quarter valued at about $155,000. Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics during the first quarter worth about $200,000. Finally, Hsbc Holdings PLC bought a new stake in Astria Therapeutics during the second quarter worth about $171,000. Institutional investors and hedge funds own 98.98% of the company’s stock.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.